Cellbion Co

Cellbion Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Cellbion Co (308430.KQ) as of Oct 25, 2026 is -63.52. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -73.73 — a change of -13.86% (higher).

P/CF

-63.52

YoY

-13.86%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Cellbion Co is 2025 -63.52 . P/CF (Price-to-Cash-Flow Ratio) of Cellbion Co was 2024 -73.73 . It decreases by -13.86% higher compared to the previous year.

The Cellbion Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2021
-100.91 KRW
Jan 1, 2022
-75.91 KRW
Jan 1, 2023
-89.49 KRW
Jan 1, 2024
-73.73 KRW
Jan 1, 2025
-63.52 KRW
The Cellbion Co P/CF history
YEARP/CFYoY
-63.52-13.86%
-73.73-17.61%
-89.49+17.90%
-75.91-24.78%
-100.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

P/CF (Price-to-Cash-Flow Ratio) of Cellbion Co is -63.52 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Cellbion Co changed from -73.73 to -63.52, representing a -13.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Cellbion Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Cellbion Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Cellbion Co